|Bid||160.81 x 900|
|Ask||160.84 x 800|
|Day's Range||159.86 - 161.16|
|52 Week Range||114.27 - 197.00|
|Beta (3Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.96 (1.89%)|
|1y Target Est||N/A|
Yahoo Finance's Brian Sozzi, Alexis Christoforous, and Alexis Keenan discuss the impending settlement between the state of Ohio and two pharmaceutical companies over the opioid crisis.
Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.
Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.
The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
Allergan chief executive Brent Saunders disclosed the role of JPMorgan and Wachtell, Lipton, Rosen & Katz asadvisers to the company on its planned sale to AbbVie, not AbbVie chief executive Richard Gonzalez ...
Top advisory shops, including the likes of Goldman Sachs and Morgan Stanley, have long shunned activists for fear of alienating their corporate clients. As a result, shareholder activism has become a lucrative business for banks hoping to cosy up to corporates in search of future business and hefty fees.
Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.
JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie. the $120m paid to Morgan Stanley for advising US agribusiness Monsanto on its $66bn sale to Germany’s Bayer in 2016, according to data from Dealogic. The details of the fee arrangement were disclosed by Allergan this week as it prepares for a shareholder vote on its sale to Chicago-based AbbVie.
Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade. "We did not anticipate revenue coming in the second quarter in a meaningful way," Chief Executive Officer David Moatazedi told Reuters in an interview. Evolus, whose shares rose 1.6% in premarket trading, expects to achieve the number two market position in the next 24 months.
Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations. Jeuveau, a neurotoxin drug to treat forehead wrinkles, was launched on May 15 and competes with Botox, which has grown to dominate the medical aesthetics market since it was launched in 2002. Evolus has rolled out a marketing program called J.E.T (Jeuveau Experience Treatment) that ties up with medical aesthetics clinics to provide new customers with up to three shipments of the treatment for free.
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Growth in sales of anti-wrinkle treatment Botox and dermal filler Juvaderm helped drive Allergan Plc to an earnings beat on Tuesday, but gains were offset by a decline in Restasis and CoolSculpting sales.
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.
Allergan (AGN) delivered earnings and revenue surprises of 0.92% and 3.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Allergan (NYSE: AGN ) reported second-quarter earnings of $4.38 per share, which beat the analyst consensus estimate of $4.34 by 0.92%. This is a 0.9% decrease over earnings of $4.42 per share from the ...